Table 2.
On-demand therapies and long-term prophylaxes used by the patients before the primary vaccination cycle.
| On-Demand Therapy | HAE (n = 185) | AAE (n = 23) |
|---|---|---|
| Icatibant; n (%) | 121 (65.4) | 15 (65.2) |
| Plasma-derived C1-INH (Berinert® by CSL Behring); n (%) | 93 (50.3) | 8 (34.8) |
| Tranexamic acid; n (%) | 9 (4.9) | - |
| Long-term prophylaxis | ||
| No long-term prophylaxis; n (%) | 105 (56.8) | 14 (61) |
| Tranexamic acid; n (%) | 2 (1.1) | 5 (21.8) |
| Danazol; n (%) | 32 (17.3) | 1 (4.3) |
| Lanadelumab; n (%) | 25 (13.5) | 2 (8.6) |
| Experimental †; n (%) | 2 (1.1) | - |
| Plasma-derived C1-INH (Berinert® by CSL Behring); n (%) | 6 (3.2) | 1 (4.3) |
| Plasma-derived C1-INH (Cinryze® by Takeda); n (%) | 13 (7) | - |
† Intended as berotralstat, used for compassionate use.